Fosigotifator + Placebo
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ALS
Conditions
ALS, Amyotrophic Lateral Sclerosis
Trial Timeline
Sep 22, 2021 → Jul 15, 2025
NCT ID
NCT04948645About Fosigotifator + Placebo
Fosigotifator + Placebo is a phase 1 stage product being developed by AbbVie for ALS. The current trial status is terminated. This product is registered under clinical trial identifier NCT04948645. Target conditions include ALS, Amyotrophic Lateral Sclerosis.
What happened to similar drugs?
4 of 12 similar drugs in ALS were approved
Approved (4) Terminated (0) Active (8)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06618118 | Phase 1 | Terminated |
| NCT04948645 | Phase 1 | Terminated |
Competing Products
20 competing products in ALS